Lunasin-induced regulation of disease-related gene expression
View Patent ↗Methods are provided for screening a test compound for anti-neoplastic activity by providing a test compound to a cancer cell and measuring the acetylation of Lysine 16 of the N-terminal tail of histone H4. Methods are also provided for using a test compound for staging a cancer tissue and for measuring the degree of the test compound's anti-neoplastic activity upon a cancer tissue by providing a test compound to a cancer tissue sample and measuring the degree of methylation of nucleotides within the 5′ region in the cancer tissue sample.
1. A method for screening a test compound for anti-neoplastic activity, the method comprising: providing a test compound, providing a cell, measuring and quantifying the degree of increase in the acetylation of Lysine 16 of the N-terminal tail of histone H4, exposing the cell to the test compound, and re-measuring the acetylation of Lysine 16 of the N-terminal tail of histone H4 in the cell, wherein the method further comprises measuring the expression of UGT1A and THBS, both before and after exposure to the test compound, wherein a two-fold increase in acetylation of Lysine 16 of the N-terminal tail of histone H4, together with an increased level of expression of UGT1A and THBS corresponds to the classification of the test compound as putatively having anti-neoplastic activity.
2. The method of claim 1 wherein the test compound is a variant or derivative of lunasin.
3. The method of claim 1 wherein the cell is an RWPE cell.
4. The method of claim 1 further comprising measuring the degree of methylation of nucleotides within the CpG island in the promoter region of the thrombospondin gene before and after exposure of the cell to the test compound, wherein a decrease in methylation corresponds to the classification of the test compound as putatively having anti-neoplastic activity.
5. The method of claim 1 wherein the test compound is a soybean protein.
6. The method of claim 1 further comprising measuring the expression of the chemopreventative gene UGT1A, before and after exposure to the test compound, wherein increased expression corresponds to the classification of the test compound as putatively having anti-neoplastic activity.
7. The method of claim 1 further comprising measuring the expression of the chemopreventative thrombospondin gene (THBS), before and after exposure to the test compound, wherein increased expression corresponds to the classification of the test compound as putatively having anti-neoplastic activity.
8. The method of claim 1 wherein the cell is derived from prostate tissue.